Development of lymphoma in patients with primary Sjögren syndromes
Journal Title: International Journal of Clinical Rheumatology - Year 2019, Vol 14, Issue 2
Abstract
Background: Lymphoma is the main complication of primary Sjögren syndrome (pSS). The aim of this study was to describe the prevalence and incidence rate of lymphoma in patients with pSS in eleven centers in Argentina. To determine the frequency of commitment of the domains of the baseline clinical ESSDAI in the patients who developed lymphoma in the course of their follow-up and compare it with the rest of the sample. Methods and findings: We included patients older than 18 years with a diagnosis of pSS according to American College of Rheumatology/European League against Rheumatism (ACR/EULAR)2002/2016 criteria, included in a multi-center Argentine database. Patients diagnosed with another associated autoimmune rheumatic disease were excluded. Six hundred and eighty one patients were included, 95% female, with a mean age of 54.41 years (± 13.70). Sixteen patients presented lymphoma (prevalence: 2.35%, 95% CI: 1.2-3.4%). The average follow-up time was 4.7 years (± 4.94). Six hundread and thirty three patients contributed data for the survival analysis. The incidence rate of lymphoma was 0.54 per 100 patient-years (95% CI: -0,26 a 1,34). The most frequently lymphoma type was MALT. Patients who developed lymphoma had a higher frequency of involvement of most of the domains of the baseline clinical ESSDAI compared to patients who did not present this complication, observing statistically significant differences in glandular (68,75% vs 28.69%, p:0,001), and cutaneous (31.25% vs 10.99%, p: 0.01) domains. The glandular domain of clinical ESSDAI was the main domain associated lymphoma development (H.R: 4.54, 95% CI: 1.57-13.12). Conclusion: This was the first study with data on the population of Argentina about the prevalence of lymphoma in patients diagnosed with Sjogren's syndrome. The prevalence of lymphoma in our cohort was lower than previously published. Despite observing a lower frequency of lymphoma in our study, we found an association with risk markers described in the literature, such as baseline parotidomegaly and cutaneous involvement.
Authors and Affiliations
Schenone LN, Pellet AC, Mamani M, Melo F, Adrover M, Barreira J, Dermarchi J, Escobar CS, Santiago L, Salvatierra G, Nitsche A, Asnal C, Amitrano C, Pucci P, Crow C, Ratti L, Cruzat V, Papasidero S, Caeiro F, Retamozo S, Saurit V, Baenas D, Riscanevo N, Gobbi C, Albiero E, Vélez S, Juarez V, Secco A
Keywords
Related Articles
- EP ID EP615926
- DOI -
- Views 46
- Downloads 0
Psychological status is associated with drug efficacy in patients with ankylosing spondylitis
Background: Quality of life in patients with Ankylosing Spondylitis (AS) is significantly associated with psychological disorders, such as depression and anxiety. Effective prevention and control of depression and anxiet...
Body image in lupus: Is it disease activity, physical function, depression, pain, fatigue, sleep, fibromyalgia or stress?
Patients with systemic lupus erythematosus (SLE) frequently experience poor body image (BI), an important issue, though not well researched or understood thus far. BI is perception of one’s own body. The effects of disea...
Adalimumab induced chronic interstitial nephritis: a controlled blinded trial in mice
Background: Adalimumab is a known drug modifying agent for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) treatment. However little is known about the risk of nephrotoxicity. To determine whether the i...
Osteoarthritis: From complications to cure
Osteoarthritis (OA) is a degenerative disorder that affects the cartilage of bones and characterized by severe pain in joint, joint lock and instability. Factors associated with its risks are obesity, past trauma, advanc...
Peripheral blood biomarkers in systemic sclerosis -associated interstitial lung diseases
Interstitial lung disease (ILD) can lead to significant morbidity and excess mortality in systemic sclerosis (SSc) patients. The early identification of patients at risk of progressive ILD is the main challenges for trea...